참고문헌
- Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA (2011). Risk of cancer in a large cohort of U.S. Veterans with diabetes. Int J Cancer, 128, 635-43. https://doi.org/10.1002/ijc.25362
- Awoniyi O, Rehman R, Dagogo-Jack S (2013). Hypoglycemia in patients with type 1 diabetes: Epidemiology, pathogenesis, and prevention. Curr Diab Rep, 13, 669-78. https://doi.org/10.1007/s11892-013-0411-y
- Bach PB, Kattan MW, Thornquist MD, et al (2003). Variations in lung cancer risk among smokers. J Natl Cancer Inst, 95, 470-8. https://doi.org/10.1093/jnci/95.6.470
- Bodmer M (2012). Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer, 78, 133-7. https://doi.org/10.1016/j.lungcan.2012.08.010
- Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006). Increased Cancer-Related Mortality for Patients with Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care, 29, 254-8. https://doi.org/10.2337/diacare.29.02.06.dc05-1558
- Bruske-Hohlfeld I (2009). Environmental and occupational risk factors for lung cancer. Methods Mol Biol, 472, 3-23. https://doi.org/10.1007/978-1-60327-492-0_1
- Cassidy A, Myles JP, van Tongeren M, et al (2008). The LLP risk model: An individual risk prediction model for lung cancer. Br J Cancer, 98, 270-6. https://doi.org/10.1038/sj.bjc.6604158
- Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012). Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab, 97, E1170-5. https://doi.org/10.1210/jc.2012-1162
- Decensi A, Puntoni M, Goodwin P, et al (2010). Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila), 3, 1451-61. https://doi.org/10.1158/1940-6207.CAPR-10-0157
- Ding J, Tang J, Chen X, et al (2013). Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus. Asian Pac J Cancer Prev, 14, 5675-80. https://doi.org/10.7314/APJCP.2013.14.10.5675
- Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
- Ehrlich SF, Quesenberry CJ, Van Den Eeden SK, Shan J, Ferrara A (2010). Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care, 33, 55-60. https://doi.org/10.2337/dc09-0880
- Ferrara A, Lewis JD, Quesenberry CJ, et al (2011). Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care, 34, 923-9. https://doi.org/10.2337/dc10-1067
- Franciosi M, Lucisano G, Lapice E, et al (2013). Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One, 8, 71583. https://doi.org/10.1371/journal.pone.0071583
- Gallagher EJ, LeRoith D (2011). Diabetes, cancer, and metformin: Connections of metabolism and cell proliferation. Ann N Y Acad Sci, 1243, 54-68. https://doi.org/10.1111/j.1749-6632.2011.06285.x
- Gao Y, Goldstein AM, Consonni D, etal (2009). Family history of cancer and nonmalignant lung d iseases as risk factors for lung cancer. Int J Cancer, 125, 146-52. https://doi.org/10.1002/ijc.24283
- Govindarajan R, Ratnasinghe L, Simmons DL, et al (2007). Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol, 25, 1476-81. https://doi.org/10.1200/JCO.2006.07.2777
- Gu Y, Wang C, Zheng Y, et al (2013). Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: A cohort study in Shanghai. PLoS One, 8, 53411. https://doi.org/10.1371/journal.pone.0053411
- Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD (2005). Diabetes and the risk of lung cancer. Diabetes Care, 28, 590-4. https://doi.org/10.2337/diacare.28.3.590
- Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
- Hsieh MC, Lee TC, Cheng SM, et al (2012). The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res, 2012, 413782.
- Jalving M, Gietema JA, Lefrandt JD, et al (2010). Metformin: Taking away the candy for cancer? Eur J Cancer, 46, 2369-80. https://doi.org/10.1016/j.ejca.2010.06.012
- Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
- Johnson JA, Yasui Y (2010). Glucose-lowering therapies and cancer risk: The trials and tribulations of trials and observations. Diabetologia, 53, 1823-6. https://doi.org/10.1007/s00125-010-1780-2
- Kao CH, Sun LM, Chen PC, et al (2013). A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? Ann Oncol, 24, 523-30. https://doi.org/10.1093/annonc/mds472
- Lai SW, Liao KF, Chen PC, et al (2012). Antidiabetes drugs correlate with decreased risk of lung cancer: A populationbased observation in Taiwan. Clin Lung Cancer, 13, 143-8. https://doi.org/10.1016/j.cllc.2011.10.002
- Lam WK, White NW, Chan-Yeung MM (2004). Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis, 8, 1045-57.
- Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A (2014). New perspective for an old antidiabetic drug: Metformin as anticancer agent. Cancer Treat Res, 159, 355-76. https://doi.org/10.1007/978-3-642-38007-5_21
- Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5. https://doi.org/10.2337/dc08-2175
- Long YC, Zierath JR (2006). AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest, 116, 1776-83. https://doi.org/10.1172/JCI29044
- Luo J, Chlebowski R, Wactawski-Wende J, et al (2012). Diabetes and lung cancer among postmenopausal women. Diabetes Care, 35, 1485-91. https://doi.org/10.2337/dc11-2108
- Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M (2012). The effect of metformin and thiazolidinedione use on lung cancer in diabetics. Bmc Cancer, 12, 410. https://doi.org/10.1186/1471-2407-12-410
- Mulshine JL, Sullivan DC (2005). Clinical practice. Lung cancer screening. N Engl J Med, 352, 2714-20. https://doi.org/10.1056/NEJMcp042630
- Noto H, Goto A, Tsujimoto T, Noda M (2012). Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS One, 7, 33411. https://doi.org/10.1371/journal.pone.0033411
- Ogunleye AA, Ogston SA, Morris AD, Evans JM (2009). A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer, 101, 1199-201. https://doi.org/10.1038/sj.bjc.6605240
- Okumura T (2010). Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol, 45, 1097-102. https://doi.org/10.1007/s00535-010-0310-9
- Rousseau M, Parent M, Pollak MN, Siemiatycki J (2006). Diabetes mellitus and cancer risk in a population-based case-controlstudy among men from Montreal, Canada. Int J Cancer, 118, 2105-9. https://doi.org/10.1002/ijc.21600
- Ruano-Ravina A, Figureueiras A, Barros-Dios JM (2003). Lung cancer and related risk factors: An update of the literature. Public Health, 117, 149-56. https://doi.org/10.1016/S0033-3506(02)00023-9
- Ruiter R, Visser LE, van Herk-Sukel MP, et al (2012). Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: Results from a large populationbased follow-up study. Diabetes Care, 35, 119-24. https://doi.org/10.2337/dc11-0857
- Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S (2013). The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care, 36, 124-9. https://doi.org/10.2337/dc12-0740
- Soranna D, Scotti L, Zambon A, et al (2012). Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist, 17, 813-22. https://doi.org/10.1634/theoncologist.2011-0462
- Spitz MR, Hong WK, Amos CI, et al (2007). A risk model for prediction of lung cancer. J Natl Cancer Inst, 99, 715-26. https://doi.org/10.1093/jnci/djk153
- Staimez LR, Weber MB, Narayan KM, Oza-Frank R (2013). A systematic review of overweight, obesity, and type 2 diabetes among Asian American subgroups. Curr Diabetes Rev, 9, 312-31. https://doi.org/10.2174/15733998113099990061
- Tammemagi CM, Pinsky PF, Caporaso NE, et al (2011). Lung cancer risk prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst, 103, 1058-68. https://doi.org/10.1093/jnci/djr173
- Tobias A (1999). Assessing the influence of a single study in the meta-analysis estimate.15-7.
- Tong GX, Cheng J, Chai J, et al (2014). Association between gestational diabetes mellitus and subsequent risk of cancer: A systematic review of epidemiological studies. Asian Pac J Cancer Prev, 15, 4265-9. https://doi.org/10.7314/APJCP.2014.15.10.4265
- Tyczynski JE, Bray F, Parkin DM (2003). Lung cancer in Europe in 2000: Epidemiology, prevention, and early detection. Lancet Oncol, 4, 45-55. https://doi.org/10.1016/S1470-2045(03)00960-4
- van Staa TP, Patel D, Gallagher AM, de Bruin ML (2012). Glucose-lowering agents and the patterns of risk for cancer: A study with the General Practice Research Database and secondary care data. Diabetologia, 55, 654-65. https://doi.org/10.1007/s00125-011-2390-3
- Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009). Diabetes and cancer. Endocr Relat Cancer, 16, 1103-23. https://doi.org/10.1677/ERC-09-0087
- Wang SY, Chuang CS, Muo CH, et al (2013). Metformin and the incidence of cancer in patients with diabetes: A nested case-control study. Diabetes Care, 36, e155-6.
- Wells GA, Shea B, O'Connell D, et al (2013). The Newcastle- Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed April 3, 2013.
- Wu CY, Hu HY, Pu CY, Huang N, Shen HC, Li CP, Chou YJ (2011). Pulmonary tuberculosis increases the risk of lung cancer: A population-based cohort study. Cancer, 117, 618-24. https://doi.org/10.1002/cncr.25616
- Yang X, Xu C, Sun Y, Han R (2013). Diabetes mellitus increases the risk of bladder cancer: An updated meta-analysis. Asian Pac J Cancer Prev, 14, 2583-9. https://doi.org/10.7314/APJCP.2013.14.4.2583
- Zabetian A, Keli HM, Echouffo-Tcheugui JB, Narayan KM, Ali MK (2013). Diabetes in the middle east and north africa. Diabetes Res Clin Pract, 101, 106-22. https://doi.org/10.1016/j.diabres.2013.03.010
피인용 문헌
- Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6621
- Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies vol.9, pp.5, 2017, https://doi.org/10.3390/cancers9050045
- Metformin use and young age lung cancer: A case series report vol.11, pp.4, 2016, https://doi.org/10.3892/ol.2016.4307
- High-concentration glucose enhances invasion in invasive ductal breast carcinoma by promoting Glut1/MMP2/MMP9 axis expression vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5843
- Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer vol.29, pp.9, 2018, https://doi.org/10.1007/s10552-018-1058-4
- Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis vol.2019, pp.1875-8630, 2019, https://doi.org/10.1155/2019/6230162